var data={"title":"Dabigatran: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dabigatran: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/361610?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dabigatran-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dabigatran: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20303809\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Thrombotic events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Premature discontinuation of dabigatran increases the risk of thrombotic events. If anticoagulation with dabigatran is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Spinal/Epidural hematoma:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Epidural or spinal hematomas may occur in patients treated with dabigatran who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include use of indwelling epidural catheters; concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, or other anticoagulants; a history of traumatic or repeated epidural or spinal punctures; a history of spinal deformity or spinal surgery; optimal timing between the administration of dabigatran and neuraxial procedures is not known.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10968125\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Pradaxa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209555\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Pradaxa</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209558\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticoagulant;</li>\n      <li>\n        Anticoagulant, Direct Thrombin Inhibitor;</li>\n      <li>\n        Direct Oral Anticoagulant (DOAC)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211475\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT and pulmonary embolism (treatment and prevention):</b> Oral: 150 mg twice daily (after 5 to 10 days of parenteral anticoagulation). <b>Note:</b> LMWH is preferred over oral anticoagulation for treatment of patients <i>with</i> cancer.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duration of therapy:</i> Optimal duration of therapy is unknown and is dependent on many factors, such as whether provoking events were present, patient risk factors for recurrence and bleeding, and individual preferences; however, ACCP guidelines recommend the following:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Long-term (first 3 months): </i>3 months is the minimum duration for most patients <i>without</i> cancer following their first episode of VTE (provoked or unprovoked) (Kearon 2012; Kearon 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Extended therapy (after first 3 months and no scheduled stop date):</i> May be considered in patients with unprovoked first DVT of the leg or PE who do not have a high bleeding risk. Extended therapy is recommended in patients with unprovoked second DVT of the leg or PE who do not have a high risk of bleeding. In patients <i>with</i> cancer, extended therapy is recommended, although high bleeding risk confers a lower grade of recommendation. All patients receiving extended therapy should be reassessed at periodic intervals for continuing use of therapy (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation (to reduce the risk of stroke and systemic embolism):</b> Oral: 150 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative thromboprophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hip replacement surgery: Initial: 110 mg given 1 to 4 hours after completion of surgery and establishment of hemostasis; if not initiated on the day of surgery, initiate therapy with 220 mg once daily after hemostasis has been achieved; maintenance: 220 mg once daily (total duration of therapy: 28 to 35 days; ACCP recommendation [Guyatt 2012]: Minimum of 10 to 14 days; extended duration of up to 35 days suggested).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Knee replacement surgery (off-label use): Initial: 110 mg given 1 to 4 hours after completion of surgery and establishment of hemostasis <b>OR</b> 220 mg as 1 dose in postoperative patients in whom therapy is not initiated on day of surgery regardless of reason; maintenance: 220 mg once daily (Eriksson 2007a) (total duration of therapy: 6 to 10 days; ACCP recommendation [Guyatt 2012]: Minimum of 10 to 14 days; extended duration of up to 35 days suggested).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Conversion from one anticoagulant to another:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from a parenteral anticoagulant:</i> Initiate dabigatran &le;2 hours prior to the time of the next scheduled dose of the parenteral anticoagulant (eg, enoxaparin) or at the time of discontinuation for a continuously administered parenteral drug (eg, IV heparin); discontinue parenteral anticoagulant at the time of dabigatran initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion to a parenteral anticoagulant: </i>Wait 12 hours (CrCl &ge;30 mL/minute) or 24 hours (CrCl &lt;30 mL/minute) after the last dose of dabigatran before initiating a parenteral anticoagulant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion from warfarin:</i> Discontinue warfarin and initiate dabigatran when INR &lt;2.0</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Conversion to warfarin:</i> Since dabigatran contributes to INR elevation, warfarin's effect on the INR will be better reflected only after dabigatran has been stopped for &ge;2 days. Start time must be adjusted based on CrCl:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &gt;50 mL/minute: Initiate warfarin 3 days before discontinuation of dabigatran</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute: Initiate warfarin 2 days before discontinuation of dabigatran</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 15 to 30 mL/minute: Initiate warfarin 1 day before discontinuation of dabigatran.</p>\n    <p style=\"text-indent:0em;margin-left:4em;\">CrCl &lt;15 mL/minute: There are no recommendations provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Dosing adjustment with concomitant medications:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DVT and pulmonary embolism (treatment and prevention):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Any P-glycoprotein inducer (eg, rifampin):</i> Avoid concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Any P-glycoprotein inhibitor (eg, amiodarone, clarithromycin, dronedarone, quinidine, verapamil, and others) with CrCl &lt;50 mL/minute:</i> Avoid concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dronedarone or ketoconazole (oral) with CrCl 30 to 50 mL/minute:</i> Reduce dabigatran dose to 75 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Any P-glycoprotein inducer (eg, rifampin):</i> Avoid concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Any P-glycoprotein inhibitor (eg, amiodarone, clarithromycin, dronedarone, quinidine, verapamil, and others) with CrCl &lt;30 mL/minute:</i> Avoid concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Postoperative thromboprophylaxis (hip replacement):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Any P-glycoprotein inducer (eg, rifampin):</i> Avoid concurrent use.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Any P-glycoprotein inhibitor (eg, amiodarone, clarithromycin, dronedarone, quinidine, verapamil, and others) with CrCl &lt;50 mL/minute:</i> Avoid concurrent use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211476\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT and pulmonary embolism/Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism)/postoperative thromboprophylaxis:</b> Oral: Numerous reports of excess anticoagulation, including fatalities, have been observed with use in older adults (ISMP [Smetzer 2012]; ISMP [Smetzer 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &gt;65 years: Refer to adult dosing. No dosage adjustment required unless renal impairment exists; however, risk of bleeding increases with age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &ge;75 years: <b>Use with extreme caution or consider other treatment options (see Warnings/Precautions) </b>(ISMP [Smetzer 2012]; ISMP [Smetzer 2015])<b>.</b> No dosage adjustment provided in manufacturer&rsquo;s labeling based on age alone (unless renal impairment coexists); however, risk of bleeding increases with age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211477\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Clinical trial evaluating safety and efficacy utilized the Cockcroft-Gault formula with the use of actual body weight (data on file; Boehringer Ingelheim Pharmaceuticals Inc 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer&rsquo;s labeling: Adults:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>DVT and pulmonary embolism (treatment and prevention):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 mL/minute: No dosage adjustment necessary <b>unless</b> patient has a CrCl &lt;50 mL/minute and is receiving concomitant P-gp inhibitors, then avoid coadministration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Patients with CrCl &lt;30 mL/minute (Schulman 2009; Schulman 2011) or CrCl &le;30 mL/minute (Schulman 2013) were excluded from the respective clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Patients receiving hemodialysis were excluded from clinical trials (Schulman 2009; Schulman 2011; Schulman 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation (to prevent stroke and systemic embolism):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary. Use with caution in mild renal impairment (CrCl 50 to 80 mL/minute) due to risk for increased dabigatran exposure (area under the curve may be increased 1.5 times higher than normal).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 50 mL/minute: No dosage adjustment necessary <b>unless</b> patient receiving concomitant dronedarone or oral ketoconazole, then reduce dabigatran to 75 mg twice daily. Use with caution in moderate renal impairment due to risk for increased dabigatran exposure (area under the curve may be increased 3 times higher than normal), particularly if patient is also of advanced age. In patients with moderate-to-severe chronic kidney disease, dose reduction may be considered although safety and efficacy of this approach has not been established (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 15 to 30 mL/minute: 75 mg twice daily <b>unless</b> patient receiving concomitant P-gp inhibitor, then avoid concurrent use. <b>Note:</b> Patients with CrCl &lt;30 mL/minute were excluded from the RE-LY trial (Connolly 2009). Dose based on pharmacokinetic data; safety and efficacy has not been established. Per the American College of Chest Physicians, dabigatran is considered contraindicated in patients with severe renal impairment (CrCl &le;30 mL/minute) (Guyatt 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Per the American College of Chest Physicians, dabigatran is considered contraindicated in patients with severe renal impairment (CrCl &le;30 mL/minute) (Guyatt 2012). In addition, the AHA/ACC/HRS does not recommend dabigatran for patients with AF and end-stage chronic kidney disease (January 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). The AHA/ACC/HRS does not recommend dabigatran for patients with AF on hemodialysis (January 2014). <b>Note:</b> Hemodialysis removes ~57% over 4 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative thromboprophylaxis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;30 mL/minute: No dosage adjustment necessary <b>unless</b> patient has a CrCl &lt;50 mL/minute and is receiving concomitant P-gp inhibitors, then avoid coadministration. <b>Note:</b> In patients with moderate impairment (CrCl 30 to 50 mL/minute), the use of dabigatran 150 mg once daily in Caucasian patients undergoing total hip or knee replacement achieved similar geometric mean steady state trough concentrations to those seen in patients with mild impairment (CrCl 50 to &lt;80 mL/minute) receiving 220 mg once daily (Eriksson 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &le;30 mL/minute: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). Patients with CrCl &lt;30 mL/minute were excluded from clinical trials (Eriksson 2007a; Eriksson 2007b; Eriksson 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alternate recommendations: </b> Geriatric patients &ge;65 years: CrCl &lt;30 mL/minute: Avoid use due to increased risk of bleeding (Beers Criteria [AGS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211478\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; consistent changes in exposure or pharmacodynamics were not observed in a study of patients with moderate impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46885726\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">The International Society on Thrombosis and Haemostasis (ISTH) 2016 guideline suggests avoiding the use of dabigatran (and other direct oral anticoagulants) in patients with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg due to the lack of clinical data in this population. If used in a patient with a BMI &gt;40 kg/m<sup>2</sup> or weight &gt;120 kg, ISTH suggests measuring peak and trough levels using ecarin clotting time or dilute thrombin time with appropriate calibration or mass spectrometry. If drug level is below the expected range, ISTH suggests changing to a vitamin K antagonist rather than adjusting the dose of dabigatran (ISTH [Martin 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10924947\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pradaxa: 75 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pradaxa: 75 mg [contains fd&amp;c yellow #6 (sunset yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pradaxa: 110 mg, 150 mg [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pradaxa: 150 mg [contains fd&amp;c blue #2 (indigotine), fd&amp;c yellow #6 (sunset yellow)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20452763\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10925866\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10925306\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf#page=24&amp;token=ICQn95T9ayP9h+Nxb5pnCF5Azd35yP5RaRyDHjBrKPCDYKJA3gRa7dqrDus1Xxxkw8yF5VXkqeb3gKt+mjsCCEwywlc8B1kXN1+OI160Qb+bph50kK/MLWP999z1mXsu&amp;TOPIC_ID=8926\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022512s035lbl.pdf#page=24</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211505\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer with a full glass of water without regard to meals;&nbsp;however, if dyspepsia occurs, consider administration with meals. Do not break, chew, or open capsules, as this will lead to 75% increase in absorption and potentially serious adverse reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209560\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Deep venous thrombosis and pulmonary embolism treatment and prevention:</b> Treatment of deep venous thrombosis (DVT) and pulmonary embolism in patients who have been treated with a parenteral anticoagulant for 5 to 10 days; to reduce the risk of recurrence of DVT and pulmonary embolism in patients who have been previously treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note: </b>The American College of Chest Physicians (ACCP) guidelines for VTE suggest dabigatran (or rivaroxaban, apixaban, or edoxaban) over a vitamin K antagonist as long-term anticoagulant therapy in patients with DVT of the leg or PE <b>and</b> without cancer (Kearon 2012; Kearon 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nonvalvular atrial fibrillation (to reduce the risk of stroke and systemic embolism):</b> Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> The 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines for the management of AF recommend oral anticoagulation for patients with nonvalvular AF or atrial flutter with prior stroke, TIA, or a CHA<sub>2</sub>DS<sub>2</sub>-VASc score &ge;2. As an alternative to warfarin, dabigatran may also be used for at least 3 weeks prior and 4 weeks after cardioversion in patients with AF or atrial flutter of &ge;48 hours duration or when the duration is unknown (AHA/ACC/HRS [January 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative thromboprophylaxis:</b> Prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism in patients who have undergone hip replacement surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50287197\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Postoperative thromboprophylaxis (knee replacement surgery)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13273235\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pradaxa may be confused with Plavix</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Dabigatran is identified in the Beers Criteria as a potentially inappropriate medication to be used with caution in patients 75 years and older or in geriatric patients who have a creatinine clearance less than 30 mL/minute (lack of evidence of safety and efficacy with CrCl &lt;30 mL/minute). Patients 75 years and older have an increased risk of GI bleeding compared to warfarin and to reported rates of other target-specific oral anticoagulants (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209612\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal symptoms (eg, dyspepsia, gastritis-like symptoms; 25% to 40%; dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hemorrhage (11% to 19%; major hemorrhage: &le;3%; hemorrhage [life-threatening]: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Gastrointestinal: Dyspepsia (8%; includes abdominal pain, abdominal discomfort, epigastric discomfort), gastrointestinal hemorrhage (&le;6%; major: &le;2%), gastritis (3%; includes gastroesophageal reflux disease, esophagitis, erosive gastritis, gastrointestinal hemorrhage, hemorrhagic gastritis, gastrointestinal ulcer)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Allergic edema, anaphylactic shock, anaphylaxis, angioedema, catheter site hemorrhage, cerebrovascular accident (in patients with prosthetic heart valve), decreased hematocrit, epidural hematoma (with spinal puncture or spinal/epidural anesthesia), esophageal ulcer, genitourinary tract hemorrhage, hemarthrosis, hypersensitivity reaction, intracranial hemorrhage (includes hemorrhagic stroke, subarachnoid bleeding, subdural hematoma), muscle hemorrhage, myocardial infarction, pericardial effusion (severe hemorrhagic; occurred postoperatively in patients with prosthetic heart valve; required intervention for hemodynamic compromise), retroperitoneal hemorrhage, spinal hematoma (with spinal puncture or spinal/epidural anesthesia), thrombocytopenia, thromboembolism (in patients with prosthetic heart valve), transient ischemic attacks (in patients with prosthetic heart valve)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209605\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious hypersensitivity (eg, anaphylaxis or anaphylactic shock) to dabigatran or any component of the formulation; active pathological bleeding; patients with mechanical prosthetic heart valve(s)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Severe renal impairment (CrCl &lt;30 mL/minute); bleeding diathesis, patients with spontaneous or pharmacological hemostatic impairment or clinically significant active bleeding (including GI bleeding); lesions at risk of clinically significant bleeding (eg, hemorrhagic or ischemic cerebral infarction) within previous 6 months; nursing women; concomitant therapy with strong P-glycoprotein inhibitors (eg, oral ketoconazole); concomitant use with other anticoagulants including unfractionated heparin (except when used to maintain central venous or arterial catheter patency), low molecular weight heparins, heparin derivatives (eg, fondaparinux), antithrombin agents (eg, bivalirudin), and oral anticoagulants (eg, warfarin, rivaroxaban, apixaban) except during transitioning of therapy from or to dabigatran</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209606\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding: The most common complication is bleeding, including severe and potentially fatal bleeding. Risk factors for bleeding include concurrent use of drugs that increase the risk of bleeding (eg, antiplatelet agents, heparin), renal impairment, and elderly patients (especially if low body weight). Discontinue in patients with active pathological bleeding. <b>Important:</b> Idarucizumab is commercially available and is the most effective agent for dabigatran reversal. Protamine and vitamin K do not reverse or impact anticoagulant effects of dabigatran. Dabigatran is dialyzable (~57% removed over 4 hours); however, supporting data are limited for utilizing this method. Depending on the bleeding severity, activated oral charcoal should be considered if ingestion occurred within 1 to 2 hours of presentation. The following alternative options may also be considered depending on specific clinical scenario: 4-factor unactivated prothrombin concentrate (PCC) (eg, Kcentra) or 4-factor activated prothrombin complex concentrate (aPCC) (eg, FEIBA). Some studies and case reports have shown moderate success in correcting coagulation tests with some of these agents; however, correction of coagulation tests does not imply reversal of the anticoagulation effect of the medication (AHA/ASA [Hemphill 2015; EHRA [Heidbuchel 2015]; NCS/SCCM [Frontera 2016]). Platelet concentrates should be considered when thrombocytopenia is present or long-acting antiplatelet drugs have been used.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: <b>[US Boxed Warning]: Upon premature discontinuation, the risk of thrombotic events is increased. If dabigatran must be discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider the use of another anticoagulant during the time of interruption.</b> In patients with non-valvular atrial fibrillation who had an acute ischemic stroke while receiving a DOAC (eg, dabigatran), guidelines generally support withholding oral anticoagulation until 1 to 2 weeks after the ischemic stroke (time frame may vary with shorter times for transient ischemic attack or small, non-disabling stroke and longer times for moderate-to-severe stroke) (AHA [Raval 2017]; AHA/ASA [Kernan 2014]; EHRA [Heidbuchel 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use in patients with moderate hepatic impairment (Child-Pugh class B) demonstrated large inter-subject variability; however, no consistent change in exposure or pharmacodynamics was seen. Patients with active liver disease were excluded from the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial (Connolly 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Evaluate renal function prior to and during therapy, particularly if used in patients with any degree of preexisting renal impairment or in any condition that may result in a decline in renal function (eg, hypovolemia, dehydration, concomitant use of medications with a potential to affect renal function); dabigatran concentrations may increase in any degree of renal impairment and increase the risk of bleeding. In moderate impairment, serum concentrations may increase 3 times higher than normal compared to concentrations in patients with normal renal function. However, in patients with nonvalvular AF, US labeling only requires dosage reduction in patients with severe renal impairment (CrCl 15 to 30 mL/minute) and dosing recommendations cannot be provided in patients with CrCl &lt;15 mL/minute. According to the AHA/ACC/HRS, may consider dose reduction in patients with nonvalvular AF and moderate-to-severe chronic kidney disease (CKD), although safety and efficacy of this approach has not been established; dabigatran is not recommended for patients with AF and end-stage CKD or on hemodialysis (AHA/ACC/HRS [January 2014]). According to the American College of Chest Physicians guidelines, dabigatran is considered contraindicated in patients with severe renal impairment (CrCl &le;30 mL/minute) (Guyatt 2012). Discontinue therapy in any patient who develops acute renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Valvular heart disease: Use is not recommended in patients with valvular heart disease, including the presence of a bioprosthetic heart valve (has not been evaluated); use is contraindicated in patients with mechanical prosthetic heart valves. In addition to several case reports (Chu 2012; Price 2012; Stewart 2012), one clinical trial reported significantly more thromboembolic events (valve thrombosis, stroke, TIA, and MI) and an excess of major bleeding (predominantly postoperative pericardial effusions requiring intervention for hemodynamic compromise) in patients with mechanical prosthetic heart valves receiving dabigatran compared to those receiving adjusted-dose warfarin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antithrombotic agents: Due to an increased risk of bleeding, avoid use, if possible, with other direct thrombin inhibitors (eg, bivalirudin), unfractionated heparin or heparin derivatives, low molecular weight heparins (eg, enoxaparin), fondaparinux, thienopyridines (eg, clopidogrel), GPIIb/IIIa antagonists (eg, eptifibatide), aspirin, coumarin derivatives, sulfinpyrazone, and ticagrelor. NSAIDs should be used cautiously. Appropriate doses of unfractionated heparin may be used to maintain catheter patency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug/drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult Drug Interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: <b>Use with extreme caution or consider other treatment options.</b> No dosage adjustment is recommended in the manufacturer's labeling based on age alone (unless renal impairment coexists); however, risk of bleeding increases with age. Numerous reports of excess anticoagulation, including fatalities, have been observed with use in older adults (ISMP [Smetzer 2012]; ISMP [Smetzer 2015]). In particular, an increased risk of GI bleeding has been observed in patients &ge;75 years of age despite similar efficacy observed with dabigatran in the elderly as compared to warfarin-treated patients (Graham 2015; Sharma 2015). Dabigatran is associated with more than a 5-fold variation in plasma concentrations in patients receiving the same dose, indicating a wide therapeutic range. Significant factors affecting increased dabigatran plasma concentrations have been found to be increasing age, decreased CrCl, lower body weight and female gender. Renal function was the predominant patient characteristic determining plasma concentrations, with age as the most important covariate (Reilly 2014). Depending on individual patient characteristics, particularly advanced age and potential for renal impairment, consider other treatment options, particularly in the US where lack of other available dosing options exist (ie, 110 mg dose) (Kalbalik 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Spinal or epidural hematoma: <b>[US Boxed Warning]: Spinal or epidural hematomas may occur with neuraxial anesthesia (epidural or spinal anesthesia) or spinal puncture in patients who are anticoagulated; may result in long-term or permanent paralysis. The risk of spinal/epidural hematoma is increased with the use of indwelling epidural catheters, concomitant administration of other drugs that affect hemostasis (eg, NSAIDs, platelet inhibitors, other anticoagulants), in patients with a history of traumatic or repeated epidural or spinal punctures, or a history of spinal deformity or spinal surgery. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of dabigatran is low; however, the optimal timing between the administration of dabigatran and neuraxial procedures is not known. Monitor frequently for signs and symptoms of neurologic impairment (eg, midline back pain, numbness/weakness of legs, bowel/bladder dysfunction); prompt diagnosis and treatment are necessary. In patients who are anticoagulated or pharmacologic thromboprophylaxis is anticipated, assess risks versus benefits prior to neuraxial interventions.</b> Also see &lsquo;Invasive or surgical procedures&rsquo;.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299117\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209617\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8926&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of Dabigatran Etexilate. Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by U.S. vs. Canadian labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the serum concentration of Dabigatran Etexilate. Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Dabigatran Etexilate may enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of dabigatran etexilate with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <b> Exceptions: </b>Acenocoumarol; Warfarin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiplatelet Agents (P2Y12 Inhibitors): May enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Antiplatelet Agents (P2Y12 Inhibitors) may increase the serum concentration of Dabigatran Etexilate. Specifically, clopidogrel may increase dabigatran serum concentrations. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of apixaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: May enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk for bleeding may be increased. Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling states that low dose aspirin could be considered, but the use of antiplatelets are not recommended for stroke prevention in patients with atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May decrease the serum concentration of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of Dabigatran Etexilate. Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by international labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deoxycholic Acid: Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May increase the serum concentration of Dabigatran Etexilate. Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by international labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: May enhance the anticoagulant effect of Anticoagulants. Refer to separate drug interaction content and to full drug monograph content regarding use of edoxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. Management: Some limited combined use may be indicated during periods of transition from one anticoagulant to another.  See the full edoxaban drug monograph for specific recommendations on switching anticoagulant treatment.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives: May diminish the anticoagulant effect of Anticoagulants. More specifically, the potential prothrombotic effects of some estrogens and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of estrogens against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<b> Exceptions: </b>Tibolone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May enhance the anticoagulant effect of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemin: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibritumomab Tiuxetan: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May enhance the adverse/toxic effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Dabigatran Etexilate. Management: Dose reductions and/or avoidance of this combination may be necessary. Specific recommendations vary by international labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limaprost: May enhance the adverse/toxic effect of Anticoagulants. The risk for bleeding may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lovastatin: May enhance the anticoagulant effect of Dabigatran Etexilate. Management: Consider an alternative HMG-CoA reductase inhibitor (statin) in patients taking dabigatran who require statin therapy. If used together, monitor patients closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of bleeding may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Dabigatran Etexilate. Specifically, the risk of bleeding may be increased. Management: A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of dabigatran and nonsteroidal anti-inflammatory drugs (NSAIDs). If combined, monitor patients extra closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Dabigatran Etexilate. Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible. Closely monitor for decreased levels/effects of dabigatran if concomitantly administering P-glycoprotein inducers, particularly strong inducers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: May decrease the serum concentration of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: May decrease the serum concentration of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins: May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects. Management: Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism.  Use is considered contraindicated under some circumstances. Refer to related guidelines for specific recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: May increase the serum concentration of Dabigatran Etexilate. Management: Consider giving dabigatran 2 hrs before oral quinidine; other dose reductions may be needed. Specific recommendations vary by U.S. vs Canadian labeling, renal function, and indication for dabigatran. Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban. Refer to separate drug interaction content and to full drug monograph content regarding use of rivaroxaban with vitamin K antagonists (eg, warfarin, acenocoumarol) during anticoagulant transition and bridging periods. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simvastatin: May enhance the anticoagulant effect of Dabigatran Etexilate. Management: Consider an alternative HMG-CoA reductase inhibitor (statin) in patients taking dabigatran who require statin therapy. If used together, monitor patients closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sugammadex: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: May enhance the anticoagulant effect of Dabigatran Etexilate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulodexide: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telavancin: May diminish the therapeutic effect of Anticoagulants. Specifically, telavancin may artificially increase the results of laboratory tests commonly used to monitor anticoagulant effectiveness, which could lead to incorrect decisions to decrease anticoagulant doses.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: May enhance the anticoagulant effect of Dabigatran Etexilate. Management: Carefully monitor for bleeding.  Dabigatran Canadian labeling recommends avoiding use with thrombolytic agents. Consider avoiding alteplase treatment of acute ischemic stroke in patients receiving dabigatran (see full drug monograph for details).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tibolone: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: May enhance the anticoagulant effect of Dabigatran Etexilate. Ticagrelor may increase the serum concentration of Dabigatran Etexilate. Management: Monitor closely for signs and symptoms of bleeding if dabigatran is used in combination with ticagrelor. Canadian product labeling recommends avoiding the concomitant use of these agents while US labeling makes no such recommendation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urokinase: May enhance the anticoagulant effect of Anticoagulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: May increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate. Management: Consider giving dabigatran 2 hrs before oral verapamil; other dose reductions may be needed. Specific recommendations vary by US vs Canadian labeling, renal function, and indication for dabigatran.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin E (Systemic): May enhance the anticoagulant effect of Anticoagulants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Anticoagulants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209725\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food has no effect on the bioavailability of dabigatran, but delays the time to peak plasma concentrations by 2 hours. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10924365\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6209562\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in some animal reproduction studies. An <i>ex vivo</i> human placenta dual perfusion model illustrated that dabigatran crossed the placenta at term; dabigatran etexilate mesylate (prodrug) had limited placental transfer (Bapat 2014). Data are insufficient to evaluate the safety of direct thrombin inhibitors during pregnancy; use of oral agents during pregnancy should be avoided (Guyatt 2012). Consider the risks of bleeding and stroke if used during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13940482\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if dabigatran etexilate is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer's labeling recommends a decision be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother. The use of alternative anticoagulants is preferred (Guyatt 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211507\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential; renal function prior to initiation and periodically as clinically indicated (ie, situations associated with a decline in renal function) and according to the AHA/ACC/HRS, at least annually in all patients (January 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12865073\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Routine coagulation testing is <b>not</b> required or necessary for DOACs. There are currently no FDA-approved assays or calibration reagents available.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In clinical situations when assessment of the anticoagulant effect is useful (eg, acute care, periprocedural settings), evaluating a recent creatinine clearance and time since the last dose was ingested is usually sufficient for guiding clinical decisions. The following coagulation testing may also be helpful in quantitative assessments to exclude clinically relevant dabigatran levels: dilute thrombin time, ecarin clotting time, or ecarin chromogenic assays (ACC [Tomaselli 2017]; AHA [Raval 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">If a sensitive reagent is used, normal partial thromboplastin time usually excludes clinically relevant serum concentrations although a therapeutic range has not been established for quantification. Thrombin time is highly sensitive and a normal value excludes clinically relevant levels (ACC [Tomaselli 2017]; AHA [Raval 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211503\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Prodrug lacking anticoagulant activity that is converted <i>in vivo</i> to the active dabigatran, a specific, reversible, direct thrombin inhibitor that inhibits both free and fibrin-bound thrombin. Inhibits coagulation by preventing thrombin-mediated effects, including cleavage of fibrinogen to fibrin monomers, activation of factors V, VIII, XI, and XIII, and inhibition of thrombin-induced platelet aggregation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6211464\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid; initially slow postoperatively</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 50-70 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 35%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; dabigatran etexilate is rapidly and completely hydrolyzed to dabigatran (active form) by plasma and hepatic esterases; dabigatran undergoes hepatic glucuronidation to active acylglucuronide isomers (similar activity to parent compound; accounts for &lt;10% of total dabigatran in plasma)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: 3% to 7%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 12-17 hours; Elderly: 14-17 hours; Mild-to-moderate renal impairment: 15-18 hours; Severe renal impairment: 28 hours (Stangier 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: Dabigatran: 1 hour; delayed 2 hours by food (no effect on bioavailability)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321837\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Pradaxa Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (60): $480.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">110 mg (60): $480.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (60): $480.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875351\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dabigat (BD);</li>\n      <li>Dabiran (BD);</li>\n      <li>Pradaksa (UA);</li>\n      <li>Pradaxa (AE, AR, AT, AU, BB, BE, BH, CH, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, ES, FR, GB, GR, GT, HK, HN, HR, ID, IE, IL, IN, IS, IT, JO, JP, KR, KW, LB, LT, LU, LV, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UY, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alban S, &ldquo;Pharmacological Strategies for Inhibition of Thrombin Activity,&rdquo; <i>Curr Pharm Des</i>, 2008, 14(12):1152-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/18473863/pubmed\" target=\"_blank\" id=\"18473863\">18473863</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bapat P, Kedar R, Lubetsky A, et al. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. <i>Obstet Gynecol</i>. 2014;123(6):1256-1261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/24807346/pubmed\" target=\"_blank\" id=\"24807346\">24807346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blech S, Ebner T, Ludwig-Schwellinger E, et al, &ldquo;The Metabolism and Disposition of The Oral Direct Thrombin Inhibitor, Dabigatran, in Humans,&rdquo; <i>Drug Metab Dispos</i>, 2008, 36(2):386-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/18006647/pubmed\" target=\"_blank\" id=\"18006647\">18006647</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chu JW, Chen VH, and Bunton R, &quot;Thrombosis of a Mechanical Heart Valve Despite Dabigatran,&quot; <i>Ann Intern Med</i>, 2012, 157(4):304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/22910954/pubmed\" target=\"_blank\" id=\"22910954\">22910954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Connolly SJ, Ezekowitz MD, Yusuf S, et al, &ldquo;Dabigatran Versus Warfarin in Patients With Atrial Fibrillation,&rdquo; <i>N Engl J Med</i>, 2009, 361(12):1139-51<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/19717844/pubmed\" target=\"_blank\" id=\"19717844\">19717844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28210451\"></a>Curto A, Albaladejo A, Alvarado A. Dental management of patients taking novel oral anticoagulants (NOAs): Dabigatran. <i>J Clin Exp Dent</i>. 2017;9(2):e289-e293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/28210451/pubmed\" target=\"_blank\" id=\"28210451\">28210451</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dager WE, Gosselin RC, and Roberts AJ, &ldquo;Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity,&rdquo; <i>Crit Care Med</i>, 2013, 41(5):e42-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/23474679/pubmed\" target=\"_blank\" id=\"23474679\">23474679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al, &ldquo;Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects,&rdquo; <i>Circulation</i>, 2011, 124(14):1573-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/21900088/pubmed\" target=\"_blank\" id=\"21900088\">21900088</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eikelboom JW, Wallentin L, Connolly SJ, et al, &ldquo;Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial,&rdquo; <i>Circulation</i>, 2011, 123(21):2363-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/21576658/pubmed\" target=\"_blank\" id=\"21576658\">21576658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26386350\"></a>Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. <i>Oral Dis</i>. 2016;22(1):23-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/26386350/pubmed\" target=\"_blank\" id=\"26386350\">26386350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17764540\"></a>Eriksson BI, Dahl OE, Kurth AA, et al, &ldquo;Oral Dabigatran Etexilate Versus Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolism after Total Knee Replacement: The RE-MODEL Randomized Trial,&rdquo; <i>J Thromb Haemost</i>, 2007a, 5(11):2178-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/17764540/pubmed\" target=\"_blank\" id=\"17764540\">17764540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17869635\"></a>Eriksson BI, Dahl OE, Rosencher N, et al, &ldquo;Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism after Total Hip Replacement: A Randomised, Double-Blind, Non-Inferiority Trial,&rdquo; <i>Lancet</i>, 2007b, 370(9591):949-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/17869635/pubmed\" target=\"_blank\" id=\"17869635\">17869635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ezekowitz MD, Reilly PA, Nehmiz G, et al, &ldquo;Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study),&rdquo; <i>Am J Cardiol</i>, 2007, 100(9):1419-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/17950801/pubmed\" target=\"_blank\" id=\"17950801\">17950801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. <i>Circulation</i>. 2015;131(2):157-164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/25359164/pubmed\" target=\"_blank\" id=\"25359164\">25359164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guyatt GH, Akl EA, Crowther M, et al, &ldquo;Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,&rdquo; <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/22315257/pubmed\" target=\"_blank\" id=\"22315257\">22315257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. <i>N Engl J Med</i>. 2012;366(9):864-866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/22375994/pubmed\" target=\"_blank\" id=\"22375994\">22375994</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i>. 2015;17(10):1467-1507. doi: 10.1093/europace/euv309.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/26324838/pubmed\" target=\"_blank\" id=\"26324838\">26324838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi: 10.1161/STR.0000000000000069.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/26022637/pubmed\" target=\"_blank\" id=\"26022637\">26022637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalabalik J, Rattinger GB, Sullivan J, Slugocki M, Carbone A, Rivkin A. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. <i>Drugs</i>. 2015;75(9):979-998.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/25998374/pubmed\" target=\"_blank\" id=\"25998374\">25998374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines [published correction appears in <i>Chest</i>. 2012;142(6):1698-1704]. <i>Chest</i>. 2012;141(2)(suppl):e419S-e496S. doi: 10.1378/chest.11-2301.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/22315268/pubmed\" target=\"_blank\" id=\"22315268\">22315268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE disease: CHEST guideline and expert panel report. <i>Chest</i>. 2016;149(2):315-352. doi: 10.1016/j.chest.2015.11.026.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/26867832/pubmed\" target=\"_blank\" id=\"26867832\">26867832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24788967\"></a>Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association [published correction appears in <i>Stroke</i>. 2015;46(2):e54]. <i>Stroke</i>. 2014;45(7):2160-2236. doi: 10.1161/STR.0000000000000024.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/24788967/pubmed\" target=\"_blank\" id=\"24788967\">24788967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khadzhynov D, Wagner F, Formella S, et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. <i>Thromb Haemost</i>. 2013;109(4):596-605.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/23389759/pubmed\" target=\"_blank\" id=\"23389759\">23389759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29302288\"></a>Lanau N, Mareque J, Giner L, Zabalza M. Direct oral anticoagulants and its implications in dentistry. A review of literature. <i>J Clin Exp Dent</i>. 2017:9(11):e1346-e1354.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/29302288/pubmed\" target=\"_blank\" id=\"29302288\">29302288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marlu R, Hodaj E, Paris A, et al, &ldquo;Effect of Non-Specific Reversal Agents on Anticoagulant Activity of Dabigatran and Rivaroxaban,&rdquo; <i>Thromb Haemost</i>, 2012, 108(2):217-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/22627883/pubmed\" target=\"_blank\" id=\"22627883\">22627883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost</i>. 2016;14(6):1308-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/27299806/pubmed\" target=\"_blank\" id=\"27299806\">27299806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nutescu EA, Shapiro NL, and Chevalier A, &ldquo;New Anticoagulant Agents: Direct Thrombin Inhibitors,&rdquo; <i>Cardiol Clin</i>, 2008, 26(2): 169-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/18406993/pubmed\" target=\"_blank\" id=\"18406993\">18406993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradaxa (dabigatran) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pradaxa (dabigatran) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim Canada Ltd; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Praxbind (idarucizumab) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Price J, Hynes M, Labinaz M, et al, &quot;Mechanical Valve Thrombosis With Dabigatran,&quot; <i>J Am Coll Cardiol</i>, 2012, 60(17):1710-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/23021328/pubmed\" target=\"_blank\" id=\"23021328\">23021328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Raval AN, Cigarroa JE, Chung MK, et al; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association [published corrections appear in <i>Circulation</i>. 2017;135(10):e647; <i>Circulation</i>. 2017;135(24):e1144]. <i>Circulation</i>. 2017;135(10):e604-e633. doi:10.1161/CIR.0000000000000477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/28167634/pubmed\" target=\"_blank\" id=\"28167634\">28167634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reilly PA, Lehr T, Haertter S, et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). <i>J Am Coll Cardiol</i>. 2014;63(4):321-328.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/24076487/pubmed\" target=\"_blank\" id=\"24076487\">24076487</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>N Engl J Med</i>. 2009;361(24):2342-2352.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/19966341/pubmed\" target=\"_blank\" id=\"19966341\">19966341</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulman S, Kearon C, Kakkar AK, et al, Extended Use of dabigatran, warfarin, or placebo in venous thromboembolism. <i>N Engl J Med</i>. 2013;368(8):709-718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/23425163/pubmed\" target=\"_blank\" id=\"23425163\">23425163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulman S, Kakkar AK, Schellong SM, et al, A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II). In: American Society of Hematology 2011 Annual Meeting; December 12, 2011; San Diego, CA. Abstract 205.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. <i>Circulation</i>. 2015;132(3):194-204.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/25995317/pubmed\" target=\"_blank\" id=\"25995317\">25995317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo; <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/22433576/pubmed\" target=\"_blank\" id=\"22433576\">22433576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. Signals for dabigatran and metoclopramide. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2012;17(1):1-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smetzer J, Cohen M, eds. Safety contrasts for 3 newer anticoagulants. <i>ISMP Medication Safety Alert! Acute Care Edition</i>. 2015;20(5):2-3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stangier J, Eriksson BI, Dahl OE, et al, &ldquo;Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement,&rdquo; <i>J Clin Pharmacol</i>, 2005, 45(5): 555-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/15831779/pubmed\" target=\"_blank\" id=\"15831779\">15831779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stangier J, Rathgen K, St&auml;hle H, et al, &ldquo;Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate,&rdquo; <i>Clin Pharmacokinet</i>, 2010, 49(4):259-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/20214409/pubmed\" target=\"_blank\" id=\"20214409\">20214409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart RA, Astell H, Young L, et al, &quot;Thrombosis on a Mechanical Aortic Valve Whilst Anti-Coagulated With Dabigatran,&quot; <i>Heart Lung Circ</i>, 2012, 21(1):53-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/21937274/pubmed\" target=\"_blank\" id=\"21937274\">21937274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>J Am Coll Cardiol</i>. 2017;70(24):3042-3067. doi: 10.1016/j.jacc.2017.09.1085.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/29203195/pubmed\" target=\"_blank\" id=\"29203195\">29203195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Ryn J, Stangier J, Haertter S, et al, &ldquo;Dabigatran Etexilate &ndash; A Novel, Reversible, Oral Direct Thrombin Inhibitor: Interpretation of Coagulation Assays and Reversal of Anticoagulant Activity,&rdquo; <i>Thromb Haemost</i>, 2010, 103(6):1116-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/20352166/pubmed\" target=\"_blank\" id=\"20352166\">20352166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallentin L, Yusuf S, Ezekowitz MD, et al, &ldquo;Efficacy and Safety of Dabigatran Compared With Warfarin at Different Levels of International Normalised Ratio Control for Stroke Prevention in Atrial Fibrillation: An Analysis of the RE-LY Trial,&rdquo; <i>Lancet</i>, 2010, 376(9745):975-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dabigatran-drug-information/abstract-text/20801496/pubmed\" target=\"_blank\" id=\"20801496\">20801496</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8926 Version 185.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F20303809\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F10968125\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6209555\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6209558\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6211475\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6211476\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F6211477\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F6211478\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F46885726\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F10924947\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20452763\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10925866\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F10925306\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6211505\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6209560\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50287197\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F13273235\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6209612\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6209605\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6209606\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299117\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6209617\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F6209725\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F10924365\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6209562\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F13940482\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6211507\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F12865073\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6211503\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6211464\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321837\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875351\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8926|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dabigatran-patient-drug-information\" class=\"drug drug_patient\">Dabigatran: Patient drug information</a></li></ul></div></div>","javascript":null}